FDA Reverses Decision, Agrees to Review Moderna's mRNA Flu Vaccine Application

The U.S. Food and Drug Administration (FDA) has reversed its earlier decision and agreed to review Moderna's application for its mRNA-based flu vaccine. Initially, the FDA had declined to review the application due to concerns about the study design. This reversal means that the vaccine could potentially be available before the next flu season. The decision marks a significant development in the regulatory process for Moderna's innovative flu vaccine technology. The review will take place in the United States, where both the FDA and Moderna are based. This update reflects the FDA's willingness to reconsider the application, potentially impacting flu prevention efforts in the upcoming season.